GSK’s TESARO provides update on AnaptysBio litigation

GSK subsidiary TESARO has confirmed that the Delaware Chancery Court has granted AnaptysBio’s motion to dismiss TESARO’s claim for anticipatory breach. The ruling does not address the substance of the underlying contractual dispute and has no impact on TESARO’s remaining claim for declaratory judgment, which the company says it intends to pursue at trial.

The litigation stems from allegations by AnaptysBio that TESARO failed to fulfil certain requirements of a licence agreement entered into between the parties in March 2014, and that AnaptysBio intends to revoke TESARO’s licence for dostarlimab. GSK and TESARO maintain that these allegations are entirely without merit.

Dostarlimab, marketed as Jemperli, is currently approved in over 35 countries for use in certain endometrial cancers, the most common gynaecologic cancer in the United States. The drug has seen significant commercial growth driven by label expansions in the US and EU, and a broad clinical trial programme evaluating its potential in additional cancer types including rectal, colon and head and neck cancers is ongoing.

---

---

Related Topics and Keywords

AnaptysBio litigation, GSK, gsk tesaro, tesaro